Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
AssigneeGenome Therapeutics Corporation
InventorsLynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
Life of this patent
Estimating the term…
Abstract
The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
Claims83
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid encoding a fragment of the polypeptide of SEQ ID NO.:
- 3850;
- (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid encoding 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:
- 3850;
- (b) a nucleic acid having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid encoding about 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850;
- (b) a nucleic acid having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid comprising coding sequence for Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (e) a nucleotide sequence hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid encoding a fragment of the polypeptide of SEQ ID NO.:
- 3850;
- (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);
- and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid encoding 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:
- 3850;
- (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (f) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);
- and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid encoding about 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850;
- (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);
- and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.
An isolated nucleic acid selected from the group consisting of:
- (a) a nucleic acid comprising coding sequence for Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);
- (c) a complement of (a) or (b);
- (d) an RNA of (a), (b), or (c), wherein U is substituted for T;
- and,
- (f) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);
- and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.
A polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850.
A polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850.
A polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850.
A polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys.
A polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys.
A fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850.
A fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850.
A fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850.
A fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence.
A fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence.
A vaccine comprising a polypeptide selected from the group consisting of:
- (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;
- (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;
- (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850;
- (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- and,
- (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- and a pharmaceutically acceptable carrier.
A vaccine selected from the group consisting of:
- (a) a fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (b) a fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (c) a fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (d) a fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence;
- and,
- (e) a fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence;
- and a pharmaceutically acceptable carrier.
A method for treating or preventing infection by Steptococcus pneumoniae comprising administering to a host a composition comprising a polypeptide selected from the group consisting of:
- (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;
- (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;
- (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850;
- (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- and,
- (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- with a pharmaceutically acceptable carrier.
A method for treating or preventing infection by Steptococcus pneumoniae comprising administering to a host a composition comprising a polypeptide selected from the group consisting of:
- (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;
- (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;
- (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850;
- (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- and,
- (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- with a pharmaceutically acceptable carrier.
A method for treating or preventing infection by Steptococcus pneumoniae comprising administering to a host a composition comprising a polypeptide selected from the group consisting of:
- (a) a fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (b) a fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (c) a fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (d) a fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence;
- and,
- (e) a fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence;
- with a pharmaceutically acceptable carrier.
An antibody that specifically binds to the polypeptide selected from the group consisting of:
- (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;
- (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;
- (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850;
- (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;
- and,
- (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys.
An antibody that specifically binds to the polypeptide selected from the group consisting of:
- (a) a fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (b) a fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (c) a fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.:
- 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;
- (d) a fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence;
- and,
- (e) a fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence.
Dependencies are inferred from the claim text.